Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour cells apoptosis factor - Immune System Key

Next Previous
Drug Profile

Tumour cells apoptosis factor - Immune System Key

Alternative Names: 84AA–API 14AA; Nerofe

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune System Key
  • Developer Immune System Key; University of Miami
  • Class Antineoplastics; Cardiovascular therapies; Peptide hormones
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Ovarian cancer; Triple negative breast cancer
  • Phase I Solid tumours
  • Discontinued Myocardial infarction

Most Recent Events

  • 24 Sep 2025 Phase I development in Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) is ongoing in USA (IV, Infusion) (NCT04365179)
  • 24 Sep 2025 Phase I development in Myelodysplastic-syndromes (Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion) development is ongoing USA (IV, Infusion) (NCT04365179)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia (Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top